Oxymetazoline

Oxymetazoline

Clinical data
ATC code	R01AA05 (WHO) R01AB07 (WHO), S01GA04 (WHO)
Identifiers
IUPAC name 3-(4,5-dihydro-1H-imidazol-2-ylmethyl)- 2,4-dimethyl-6-tert-butyl-phenol
CAS Number	1491-59-4
PubChem CID	4636
DrugBank	APRD01158
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C16H24N2O
Molar mass	260.375 g·mol−1
Melting point	301.5 °C (574.7 °F)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

WikiDoc Resources for Oxymetazoline
Articles
Most recent articles on Oxymetazoline Most cited articles on Oxymetazoline Review articles on Oxymetazoline Articles on Oxymetazoline in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Oxymetazoline Images of Oxymetazoline Photos of Oxymetazoline Podcasts & MP3s on Oxymetazoline Videos on Oxymetazoline
Evidence Based Medicine
Cochrane Collaboration on Oxymetazoline Bandolier on Oxymetazoline TRIP on Oxymetazoline
Clinical Trials
Ongoing Trials on Oxymetazoline at Clinical Trials.gov Trial results on Oxymetazoline Clinical Trials on Oxymetazoline at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Oxymetazoline NICE Guidance on Oxymetazoline NHS PRODIGY Guidance FDA on Oxymetazoline CDC on Oxymetazoline
Books
Books on Oxymetazoline
News
Oxymetazoline in the news Be alerted to news on Oxymetazoline News trends on Oxymetazoline
Commentary
Blogs on Oxymetazoline
Definitions
Definitions of Oxymetazoline
Patient Resources / Community
Patient resources on Oxymetazoline Discussion groups on Oxymetazoline Patient Handouts on Oxymetazoline Directions to Hospitals Treating Oxymetazoline Risk calculators and risk factors for Oxymetazoline
Healthcare Provider Resources
Symptoms of Oxymetazoline Causes & Risk Factors for Oxymetazoline Diagnostic studies for Oxymetazoline Treatment of Oxymetazoline
Continuing Medical Education (CME)
CME Programs on Oxymetazoline
International
Oxymetazoline en Espanol Oxymetazoline en Francais
Business
Oxymetazoline in the Marketplace Patents on Oxymetazoline
Experimental / Informatics
List of terms related to Oxymetazoline

Overview

Oxymetazoline is a topical decongestant used, in the form of Oxymetazoline hydrochloride, in products such as Nasivion, Vicks Sinex and Afrin. Oxymetazoline is generally available as a nasal spray. If overused it can cause a "rebound congestion" (rhinitis medicamentosa) where the tissues of the sinuses are damaged, become swollen, and therefore become congested after the drug wears off. As a result, a user can develop physiological tolerance to the drug, manifested by prolonged nasal congestion without continued use of the medication. (See the discussion of the effect of benzalkonium chloride, a common additive to oxymetazoline nasal sprays, in the article Rhinitis medicamentosa.)

The medication has sympathomimetic properties, and thus constricts the blood vessels of the nose and sinuses via activation of alpha1 adrenergic receptors, in turn causing less production of mucous. It is frequently used by anaesthesiologists to reduce nasal bleeding during nasal endotracheal intubations. This drug, not unlike most sympathomimetic amines, has adrenaline-releasing properties due to its mode of action. However, since the application is topical, it has practically no CNS stimulation as of the systemic application of decongestants such as pseudoephedrine.

Since no clinical data on exposed pregnancies are available with oxymetazoline, the safe use of oxymetazoline during pregnancy has not been established.

If accidentally ingested, standard methods to remove unabsorbed drugs should be considered. There is no specific antidote for oxymetazoline. In children, oxymetazoline may produce profound central nervous system depression.

Oxymetazoline HCl 0.025% is also the active ingredient in Visine L.R. Long-Lasting Redness Relief eye drops.

Template:SIB
he:אוקסימטזולין hu:Oxymetazolin nl:Oxymetazoline Template:WH Template:WikiDoc Sources